Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 7 January 2026 - 8 January 2026

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

New York, January 8, 2026, 05:14 (EST) — Premarket AbbVie Inc (ABBV) shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing The whiplash matters because…
8 January 2026
···
GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers

GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers

London, Jan 8, 2026, 09:12 GMT — Regular session GSK (GSK.L) shares slipped on Thursday as investors weighed upbeat headlines on its experimental hepatitis B therapy against a lack of hard cure-rate data. The stock was down 0.9% at 1,883.5 pence in London trade, after moving between 1,880 and 1,896.5 pence and staying near the top of its 52-week range.…
8 January 2026
····
Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

New York, Jan 7, 2026, 20:51 EST — Market closed Regeneron Pharmaceuticals shares climbed 4.6% on Wednesday after Bank of America upgraded the drugmaker to “Buy” from “Underperform” and raised its price objective to $860. Investing The call matters because Regeneron’s stock has been stuck in a tug-of-war: investors want proof the company can defend its eye-medicine franchise as rivals…
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

New York, Jan 7, 2026, 18:52 EST — After-hours Merck & Co (MRK.N) shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus (HPV) vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60,…
8 January 2026
···
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

New York, Jan 7, 2026, 18:35 EST — After-hours AbbVie (ABBV.N) shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2%…
8 January 2026
····
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

New York, Jan 7, 2026, 4:55 PM EST — After-hours Eli Lilly and Co shares climbed on Wednesday after the drugmaker agreed to buy Ventyx Biosciences in a $1.2 billion deal, pressing ahead with its push beyond blockbuster diabetes and weight-loss drugs. Lilly stock ended up 4.1% at $1,108.09, after touching $1,117.37, for a market value around $1 trillion. Reuters…
7 January 2026
··
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

New York, Jan 7, 2026, 15:40 (EST) — Regular session Merck & Co (MRK.N) shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics (CDTX.O) and expected to finish the acquisition through a merger later in the day. The company said the deal will…
7 January 2026
···
Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape

Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape

New York, January 7, 2026, 13:26 EST — Regular session Viasat shares fell $4.89, or about 11.3%, to $38.57 on Wednesday, a day after the stock closed at $43.46. The shares traded between $38.27 and $43.58. The drop comes as investors weigh whether Viasat’s Inmarsat business can keep landing big mobility customers that buy recurring service, not just hardware. Maritime…
7 January 2026
···
Zealand Pharma stock sinks 6% in Copenhagen — what investors watch before JPM Healthcare

Zealand Pharma stock sinks 6% in Copenhagen — what investors watch before JPM Healthcare

Copenhagen, Jan 7, 2026, 11:47 CET — Regular session Shares in Zealand Pharma (ZELA.CO) slid 6.1% to 405.5 Danish crowns by 11:27 a.m. CET, versus Tuesday’s close of 431.7, while Denmark’s OMXC25 index dipped about 0.4%. Zealand Pharma The move shows how sharply investors are trading the obesity-drug pipeline race, where small shifts in timing and trial expectations can swing…
7 January 2026
···
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

New York, January 7, 2026, 05:25 EST — Premarket Moderna (MRNA) shares fell 1.4% to $35.15 in premarket trading on Wednesday, after jumping 10.9% in the previous session to close at $35.66. The stock hit an intraday high of $36.26 on Tuesday, with about 20.2 million shares traded. StockAnalysis The moves follow Moderna’s announcement on Monday that it has filed…
7 January 2026
···
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

London, Jan 7, 2026, 07:52 GMT — Premarket GSK (GSK.L) said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than…
7 January 2026
··
Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data

Johnson & Johnson stock in focus after Tecvayli-Darzalex filing, lupus drug data

New York, January 6, 2026, 21:28 EST — Market closed Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology. The developments matter now because investors are looking for durable growth drivers heading into quarterly results later this month, when management is expected to frame demand trends and…
7 January 2026
··
1 … 10 11 12 13 14 … 46

Stock Market Today

  • Thursday Sector Leaders: Precious Metals and Metals & Mining Stocks Rally
    January 22, 2026, 1:03 PM EST. On Thursday, precious metals shares gained around 1.5%, led by Avino Silver & Gold Mines which surged 6.4%, and Harmony Gold Mining, up 5.9%. Metals & mining stocks also rose by approximately 1.3%, with Atlas Lithium soaring 16.1% and Idaho Strategic Resources climbing 7%. These moves highlight investor interest in mining sector equities amid broader market activity.
Go toTop